Fluoroquinolone resistance in neisseria gonorrhoeae: Fitness cost or benefit?

Journal of Infectious Diseases

Volumn 205, Issue 12, 2012, Pages 1775-1777

  Dillon, Jo Anne R ^a   Parti, Rajinder P ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; MACROLIDE; PENICILLIN DERIVATIVE; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CAMPYLOBACTER JEJUNI; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI; GENE LOCUS; GENE MUTATION; GONORRHEA; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; NOTE; PLASMID; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; MUTATION; NEISSERIA GONORRHOEAE;

EID: 84861566753     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis281     Document Type: Note

References (24)

1. Unemo M, Shafer WM. Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future. Ann New York Acad Sci 2011; 1230: E19-28.
2. Lewis DA. The gonococcus fights back: is this time a knock out? Sex Transm Infect 2010; 86:415-21.
3. Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high level resistance to ceftriaxone. Antimicrob Agents Chermother 2011; 55:3538-45.
4. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoul P. Highlevel cefixime-and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012; 56:1273-80.
5. Chisholm SA, Mouton JW, Lewis DA, Nichols T, Ison CA, Livermore DM. Cephalosporin MICcreep among gonococci: time for a pharmacodynamics rethink? J Antimicrob Chermother 2011; 65:2141-8.
6. Bolan GA, Sparling F, Wasserheit JN. The emerging threat of untreatable gonococcal infection. New Engl J Med 2012; 366:485-7.
7. Knapp JS, Fox KK, Trees DL, Whittington WL. Fluoroquinolone resistance in Neisseria gonorrhoeae. Emerg Infect Dis 1997; 3:33-9.
8. Tapsall J. Multidrug-resistant Neisseria gonorrhoeae. Can Med Assoc J 2009; 180:268-9.
9. Mann J, Kropp R, Wong T, Venne S, Romanowski B. Gonorrhea treatment guidelines in Canada: 2004 update. Can Med Assoc J 2004; 171:1345-6.
10. Del Rio C, Hall G, Hook EW, et al. Update to CDC's sexually transmitted diseases treatment guidelines 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR 2007; 56:332-6.
11. Yang Y, Liao M, Gu W-M, et al. Antimicrobial susceptibility and molecular determinants of quinolone resistance in Neisseria gonorrhoeae isolates from Shanghai. Antimicrob Agents Chemother 2006; 58:868-72.
12. Goold PC, Bignell CJ. No way back for quinolones in the treatment of gonorrhoea. Sex Transm Infect 2006; 82:225-6.
13. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 2010; 8:260-71.
14. Guo B, Abdelraouf K, Ledesma KR, Nikolaou M, Tam VH. Predicting bacterial fitness cost associated with drug resistance. J Antimicrob Chemother 2012; 67:928-32.
15. Karami N, Nowrouzian F, Adlerberth I, Wold AE. Tetracycline resistance in Escherichia coli and persistence in the infantile colonic microbiota. Antimicrob Agents Chemother 2006; 50:156-61.
16. Martinez JL, Baquero F. Mutation frequencies and antibiotic resistance. Antimicrob Agents Chemother 2000; 44:1771-7.
17. Haenni M, Moreillon P. Fitness cost and impaired survival in penicillin-resistant Streptococcus gordonii isolates selected in the laboratory. Antimicrob Agents Chemother 2008; 52:337-9.
18. Enne VI, Bennett PM, Livermore DM, Hall LMC. Enhancement of host fitness by the sul2-coding plasmid p9123 in the absence of selective pressure. J Antimicrob Chemother 2004; 53:958-63.
19. Marcusson LL, Frimodt-Moller N, Hughes D. Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog 2009; 5:e1000541.
20. Luo N, Pereira S, Sahin O, et al. Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure. Proc Natl Acad Sci USA 2005; 102:541-6.
21. Belland RJ, Morrison SG, Ison C, Huang WM. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone resistance. Molec Microbiol 1994; 14:371-80.
22. Jerse AE, Wu H, Packlam M, Vonick RA, Begum AA, Garvin LE. Estradiol-treated female mice as surrogate hosts for Neisseria gonorrhoeae genital tract infections. Front Microbiol 2011; 2:1-13.
23. Jerse AE, Sharma ND, Simms AN, Crow ET, Snyder L, Shafer WM. A gonococcal efflux pump system enhances bacterial survival in a female mouse model of genital tract infection. Infect Immun 2003; 71:5576-82.
24. Warner DM, Folster JP, Shafer WM, Jerse AE. Regulation of the MtrC-MtrD-MtrE efflux-pump system modulates the in vivo fitness of Neisseria gonorrhoeae. J Infect Dis 2007; 196:1804-12.